Claret Capital Partners has made an investment, through its Fund IV, of up to €28 million in Cinclus Pharma, a late‑stage clinical pharmaceutical company developing next‑generation treatments for gastric acid‑related diseases.  The proceeds will enable an earlier start of the final stage of Cinclus Pharma’s Phase III clinical programme HEEALING 1.  They will also contribute […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!